Prolonged APTT of unknown etiology: A systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit

Author(s)

Nobrega Barbosa, Ayla Cristina ^[1] ; Lima Montalvao, Silmara Aparecida ^[2] ; NObrega Barbosa, Kevan Guilherme ^[3] ; Colella, Marina Pereira ^[2] ; Annichino-Bizzacchi, Joyce Maria ^{[1, 2]} ; Ozelo, Margareth Castro ^{[1, 2]} ; De Paula, Erich Vinicius ^{[1, 2]}

Affiliation

^[1] Univ Estadual Campinas, Fac Med Sci, BR-13083970 Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Campinas, SP - Brazil

^[3] CESMAC Univ Ctr, Maceio, AL - Brazil

• Document type: Journal article
• Source: RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS; v. 3, n. 4, p. 749-757, OCT 2019.
• Web of Science Citations: 0

Abstract

Background A prolonged activated partial thromboplastin time (APTT) of unknown cause is one of the most frequent reasons why outpatients are referred for hemostasis consultation. Nevertheless, very few data are available on the relative contribution of individual causes of this common clinical scenario. Here, we present a systematic evaluation of all causes of APTT prolongation in a consecutive population of outpatients referred for specialized hemostasis consultation during a 14-year period. Methods All cases referred to an academic specialized hemostasis outpatient unit due to APTT prolongation of unknown etiology whose prolonged APTT was confirmed in the first visit were included in the study. Data were obtained from the electronic medical records. Results Among 187 consecutive patients, the most frequent causes were antiphospholipid antibodies in 22.6%, contact pathway factor deficiencies in 17.4%, other coagulation factor deficiencies in 11.6%, and vitamin K deficiency/liver disease in 11.6%. A definite cause was not identified in 22.1% of patients. Presence of antiphospholipid antibodies, and absence of bleeding symptoms were both associated with significantly longer APTT values compared to other categories/clinical scenarios. The investigation of each case required a mean of 18.2 additional tests per patient, with estimated costs ranging from US\$191.60 to US\$1055.60. Conclusions Our results describe the main causes of APTT prolongation in outpatients, as well as estimates of resource use required to investigate this condition, thus providing evidence supporting the importance of measures to minimize the indiscriminate use of this assay. (AU)

• FAPESP's process: 16/14172-6 - Investigation of the pathophysiological aspects and novel therapeutic approaches for thromboembolic disorders
• Grantee: Joyce Maria Annichino-Bizzacchi
• Support Opportunities: Research Projects - Thematic Grants